tirzepatide for osa FDA approves to treat sleep apnea Ozempic and sleep apnea: What

New indications: Semaglutide is under study for NASH/MASH, heart failure with preserved ejection fraction, chronic kidney disease and Alzheimers disease

doi: 10.1002/JLB.3HI0518-193R 66 DahlgrenCForsmanHSundqvistMBjrkmanLMrtenssonJ

long-acting incretin analog (39 amino acids) Modification: Lipidated with C20 fatty diacid via Glu-Glu linker on Lys residue

It is important to note that higher-dose semaglutide (2.4 mg, marketed as Wegovy) is licensed specifically for weight management in obesity and has separate eligibility criteria and dosing from the diabetes indication

Spending is anticipated to increase as manufacturers invest in outcome trials and larger production networks